Antibody-free quantification of seven tau peptides in human CSF using targeted mass spectrometry

Frontiers in Neuroscience

Volumn 9, Issue SEP, 2015, Pages

  Bros, Pauline ^a,b   Vialaret, Jérôme ^a   Barthelemy, Nicolas ^a   Delatour, Vincent ^b   Gabelle, Audrey ^a,c   Lehmann, Sylvain ^a   Hirtz, Christophe ^a  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b LABORATOIRE NATIONAL DE MÉTROLOGIE ET D ESSAIS LNE   (France)

^c GUI DE CHAULIAC HOSPITAL   (France)

Author keywords

Alzheimer's disease; Human cerebrospinal fluid; LC MS MS; Quantitative proteomic; Tau protein; Triple quadrupole

Indexed keywords

ANTIBODY; BIOLOGICAL MARKER; NITROGEN 15; PERCHLORIC ACID; TAU PROTEIN;

ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; ISOTOPE LABELING; LIMIT OF QUANTITATION; LUMBAR PUNCTURE; MASS SPECTROMETER; MASS SPECTROMETRY; PEPTIDE ANALYSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN METABOLISM; SENSITIVITY AND SPECIFICITY; SOLID PHASE EXTRACTION;

EID: 84946573293     PISSN: 16624548     EISSN: 1662453X     Source Type: Journal    
DOI: 10.3389/fnins.2015.00302     Document Type: Article

References (20)

1. Andreasen, N., and Blennow, K. (2005). CSF biomarkers for mild cognitive impairment and early Alzheimer's disease. Clin. Neurol. Neurosurg. 107, 165-173. doi: 10.1016/j.clineuro.2004.10.011
2. Blennow, K., and Vanmechelen, E. (2003). CSF markers for pathogenic processes in Alzheimer's disease: diagnostic implications and use in clinical neurochemistry. Brain Res. Bull. 61, 235-242. doi: 10.1016/S0361-9230(03)00086-8
3. Drechsel, D. N., Hyman, A. A., Cobb, M. H., and Kirschner, M. W. (1992). Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. Mol. Biol. Cell 3, 1141-1154. doi: 10.1091/mbc.3.10.1141
4. Gabelle, A., Roche, S., Geny, C., Bennys, K., Labauge, P., Tholance, Y., et al. (2010). Correlations between soluble alpha/beta forms of amyloid precursor protein and Abeta38, 40, and 42 in human cerebrospinal fluid. Brain Res. 1357, 175-183. doi: 10.1016/j.brainres.2010.08.022
5. Green, A. J., Harvey, R. J., Thompson, E. J., and Rossor, M. N. (1999). Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease. Neurosci. Lett. 259, 133-135. doi: 10.1016/S0304-3940(98)00904-5
6. Hanger, D. P., Lau, D. H., Phillips, E. C., Bondulich, M. K., Guo, T., Woodward, B. W., et al. (2014). Intracellular and extracellular roles for tau in neurodegenerative disease. J. Alzheimers. Dis. 40(Suppl. 1), S37-S45. doi: 10.3233/JAD-132054
7. Hernandez, F., and Avila, J. (2007). Tauopathies. Cell. Mol. Life Sci. 64, 2219-2233. doi: 10.1007/s00018-007-7220-x
8. Höglund, K., Fourier, A., Perret-Liaudet, A., Zetterberg, H., Blennow, K., and Portelius, E. (2015). Alzheimer's disease-recent biomarker developments in relation to updated diagnostic criteria. Clin. Chim. Acta. doi: 10.1016/j.cca.2015.01.041. [Epub ahead of print]
9. Huillet, C., Adrait, A., Lebert, D., Picard, G., Trauchessec, M., Louwagie, M., et al. (2012). Accurate quantification of cardiovascular biomarkers in serum using Protein Standard Absolute Quantification (PSAQ) and selected reaction monitoring. Mol. Cell. Proteomics 11:M111.008235. doi: 10.1074/mcp.M111.008235
10. Iqbal, K., Liu, F., Gong, C. X., and Grundke-Iqbal, I. (2010). Tau in Alzheimer disease and related tauopathies. Curr. Alzheimer Res. 7, 656-664. doi: 10.2174/156720510793611592
11. James, O. G., Doraiswamy, P. M., and Borges-Neto, S. (2015). PET imaging of tau pathology in Alzheimer's disease and tauopathies. Front. Neurol. 6:38. doi: 10.3389/fneur.2015.00038
12. Lehmann, S., Hoofnagle, A., Hochstrasser, D., Brede, C., Glueckmann, M., Cocho, J. A., et al. (2013). Quantitative Clinical Chemistry Proteomics (qCCP) using mass spectrometry: general characteristics and application. Clin. Chem. Lab. Med. 51, 919-935. doi: 10.1515/cclm-2012-0723
13. McAvoy, T., Lassman, M. E., Spellman, D. S., Ke, Z., Howell, B. J., Wong, O., et al. (2014). Quantification of tau in cerebrospinal fluid by immunoaffinity enrichment and tandem mass spectrometry. Clin. Chem. 60, 683-689. doi: 10.1373/clinchem.2013.216515
14. Perrin, R. J., Fagan, A. M., and Holtzman, D. M. (2009). Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature 461, 916-922. doi: 10.1038/nature08538
15. Picard, G., Lebert, D., Louwagie, M., Adrait, A., Huillet, C., Vandenesch, F., et al. (2012). PSAQ standards for accurate MS-based quantification of proteins: from the concept to biomedical applications. J. Mass Spectrom. 47, 1353-1363. doi: 10.1002/jms.3106
16. Portelius, E., Hansson, S. F., Tran, A. J., Zetterberg, H., Grognet, P., Vanmechelen, E., et al. (2008). Characterization of tau in cerebrospinal fluid using mass spectrometry. J. Proteome Res. 7, 2114-2120. doi: 10.1021/pr7008669
17. Sergeant, N., Delacourte, A., and Buee, L. (2005). Tau protein as a differential biomarker of tauopathies. Biochim. Biophys. Acta 1739, 179-197. doi: 10.1016/j.bbadis.2004.06.020
18. Sjögren, M., Davidsson, P., Gottfries, J., Vanderstichele, H., Edman, A., Vanmechelen, E., et al. (2001). The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer's disease, reflecting a common pathophysiological process. Dement. Geriatr. Cogn. Disord. 12, 257-264. doi: 10.1159/000051268
19. Smith, L. M., and Kelleher, N. L. (2013). Proteoform: a single term describing protein complexity. Nat. Methods 10, 186-187. doi: 10.1038/nmeth.2369
20. Wang, G. R., Gao, C., Shi, Q., Zhou, W., Chen, J. M., Dong, C. F., et al. (2010). Elevated levels of tau protein in cerebrospinal fluid of patients with probable Creutzfeldt-Jakob disease. Am. J. Med. Sci. 340, 291-295. doi: 10.1097/MAJ.0b013e3181e92a1f